Work

Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.e17598

Authors: Anupama Vasudevan, Sandy English, Mike Gart, Taofikat Oladipo, John Hartman, Laura L. Iadeluca, Fred J. Kudrik

Institutions: Integra (United States), GlaxoSmithKline (United States), South Carolina Oncology Associates

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4379282927

Cites:

Cited by: 3

Related to: 10